Lilly’s new weight-loss pill recommended for EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued several new recommendations on medicines, including Eli Lilly’s Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and the treatment of type 2 diabetes in adults.
By Finwire
Advertisement
The drug is taken as a once-daily tablet and, if approved, will offer an alternative to injectable and other oral GLP-1 medicines.
The CHMP also recommended extending the indications of five medicines already approved in the EU.
These included Novo Nordisk’s Kyinsu, AstraZeneca’s H5N1 pandemic influenza vaccine, Sobi’s Tryngolza and Pfizer’s Tukysa.
BREAKING